Sung H, Ferlay J, Siegel Rl, et al: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clinic, 2021; 71(3):209-249. https://doi.org/10.3322/caac.21660.

van Maaren MC, de Munck L, Strobbe LJA, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J Cancer. 2019;144:263–72. https://doi.org/10.1002/ijc.31914.

Article  CAS  PubMed  Google Scholar 

Cardoso F, Paluch-Schimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49. https://doi.org/10.1016/j.annonc.2020.09.010.

Article  CAS  PubMed  Google Scholar 

American Cancer Society. Understanding a breast cancer diagnosis. Aug 25, 2022. https://www.cancer.org/cancer/breast-cancer/ understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status. html#written_by (accessed Sept 23, 2022).

Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28(1):92–8. https://doi.org/10.1200/JCO.2008.19.9844.

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. https://doi.org/10.1056/NEJM200103153441101.

Article  CAS  PubMed  Google Scholar 

Marty M, Cognetti F, Maraninchi D, et. al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer administered as first-line treatment. J Clin Oncol. 2005;23:4265-4274. https://doi.org/10.1200/JCO.2005.04.173.

von Minckwitz G, Du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03–05 study. J Clin Oncol. 2009;27(12):1999–2006. https://doi.org/10.1200/JCO.2008.19.6618.

Article  CAS  Google Scholar 

von Minckwitz G, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3–05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47(15):2273–81. https://doi.org/10.1016/j.ejca.2011.06.021.

Article  CAS  Google Scholar 

Jackisch C, Welslau M, Schoenegg W, et al. Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - results from a prospective, observational study in Germany. Breast. 2014;23:603–8. https://doi.org/10.1016/j.breast.2014.06.0030960-9776.

Article  CAS  PubMed  Google Scholar 

Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol. 2008;5(9):531–42. https://doi.org/10.1038/ncponc1179.

Article  CAS  PubMed  Google Scholar 

Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(suppl 2):S26–35.

Article  PubMed  Google Scholar 

Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–37. https://doi.org/10.1200/JCO.2008.20.6847.

Article  CAS  PubMed  Google Scholar 

Han Y, Wang J, Liu W, et al. Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis. Cancer Manag Res. 2019;11:4699–706. https://doi.org/10.2147/CMAR.S198962.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34. https://doi.org/10.1056/NEJMoa1413513.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miles D, Ciruelos E, Schneeweiss A, et al: Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer with a multivariable approach to guide prognostication. Annals Oncol, https://doi.org/10.1016/j.annonc.2021.06.024.

Urruticoechea A, Rizwanullah M, Im SA, et al. Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. J Clin Oncol. 2017;35(26):3030–8. https://doi.org/10.1200/JCO.2016.70.6267.

Article  CAS  PubMed  Google Scholar 

Rimawi M, Ferrero JM, Haba-Rodriguez J, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36(28):2826–35. https://doi.org/10.1200/JCO.2017.76.7863.

Article  CAS  PubMed  Google Scholar 

Arpino G, de la Haba-Rodriguez J, Ferrero JM, De Placido S, et al Pertuzumab, trastuzumab, and an aromatase inhibitor for HER2-positive and hormone receptor-positive metastatic/locally Advanced Breast Cancer: PERTAIN Final Analysis. Clin Cancer Res. 2023; CCR-22-1092. https://doi.org/10.1158/1078-0432.CCR-22-1092.

National Cancer Institute, Drug Dictionary: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/margetuximab.

Rugo H, Im SA, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573–84. https://doi.org/10.1001/jamaoncol.2020.7932.

Article  PubMed  Google Scholar 

Rugo H, Im SA, Cardoso F, et al. Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial. J Clin Oncol. 2023;41:198–205. https://doi.org/10.1200/JCO.21.02937.

Article  CAS  PubMed  Google Scholar 

Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–43.

Article  CAS  PubMed  Google Scholar 

Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124–30. https://doi.org/10.1200/JCO.2008.21.4437.

Article  CAS  PubMed  Google Scholar 

Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27:5538–46. https://doi.org/10.1200/JCO.2009.23.3734.

Article  CAS  PubMed  Google Scholar 

Johnston S, Hegg R, Im SA, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor–positive metastatic breast cancer: updated results of alternative. J Clin Oncol. 2021;39:79–89. https://doi.org/10.1200/JCO.20.01894.

Article  CAS  PubMed  Google Scholar 

Murthy R, Borges VF, Conlin A, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomized, open-label, phase 1b study. Lancet Oncol. 2018;19:880–8.

Article  CAS  PubMed  Google Scholar 

•• Murthy R, Loi S, Okines A, et al: Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609. https://doi.org/10.1056/NEJMoa1914609. HER2CLIMB study demonstrated improved survival outcomes in heavily pretreated patients with advanced or metastatic HER2 positive breast cancer, after at least 2 prior anti HER2 treatment regimens, including patients with active brain metastases, providing new treatment option for this difficult to treat population.

Lin NU, Borges V, Anders CK, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38:2610–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seagen phase 3 trial of Tukysa (tucatinib) in combination with antibody-drug conjugate ado-trastuzumab emtansine meets primary endpoint of progression-free survival in patients with previously treated HER2-positive metastatic breast cancer. News release. Seagen. August 16, 2023. Accessed August 16, 2023. https://investor.seagen.com/press-releases/news-details/2023/Seagen-Phase-3-Trial-of-TUKYSA-tucatinib-in-Combination-with-Antibody-Drug-Conjugate-ado-trastuzumab-emtansine

Saura C, Oliveira M, Feng YH, et al: Neratinib plus capecitabine vs lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020.

Li Q, Guan X, Chen S, et al. Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: a phase I clinical trial. Clin Cancer Res. 2019;25(17):5212–20.

Article  CAS  PubMed  Google Scholar 

Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible Pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2017;35(27):3105–12.

Article  CAS  PubMed  Google Scholar 

Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study. J Clin Oncol. 2019;37(29):2610–9.

Article  CAS  PubMed  Google Scholar 

Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351–60.

Article  CAS  PubMed  Google Scholar 

Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16:209. https://doi.org/10.1186/bcr3621.

Article  PubMed  PubMed Central  Google Scholar 

Verma S, Miles D, Gianni L, et al. Trastuzumab emtasine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91. https://doi.org/10.1056/NEJMoa1209124.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krop IE, Kim SB, González-Martín A, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743–54. https://doi.org/10.1016/S1470-2045(17)30313-3.

Article  CAS  PubMed